Develops best-in-class, late clinical-stage metabolic and gynecology drugs addressing unmet medical needs. Portfolio includes novel therapies for preterm birth prevention (pregnant individuals at risk) and for metabolic dysfunction-associated steatohepatitis (MASH) patients.